Dr. Toppmeyer on Sequencing Therapy in HER2+ Breast Cancer
Deborah L. Toppmeyer, MD, discusses sequencing therapy in HER2-positive breast cancer.
Dr. Toppmeyer on the Utility of De-Escalation Trials in HER2+ Breast Cancer
Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512